NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $102.88 -5.43 (-5.01%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$100.88 -2.00 (-1.94%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Neurocrine Biosciences Stock (NASDAQ:NBIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$102.55▼$107.5350-Day Range$102.88▼$153.2952-Week Range$100.88▼$157.98Volume1.76 million shsAverage Volume989,062 shsMarket Capitalization$10.26 billionP/E Ratio31.27Dividend YieldN/APrice Target$165.38Consensus RatingModerate Buy Company OverviewNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More… Remove Ads Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreNBIX MarketRank™: Neurocrine Biosciences scored higher than 97% of companies evaluated by MarketBeat, and ranked 21st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 17 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth51.17% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 51.17% in the coming year, from $4.28 to $6.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 31.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.62.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 31.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.23.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.77. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.45% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 1.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Sustainability and ESG2.9 / 5Environmental Score-2.61 Percentage of Shares Shorted3.45% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 1.86%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.37 News SentimentNeurocrine Biosciences has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Neurocrine Biosciences this week, compared to 14 articles on an average week.Search InterestOnly 1 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -97% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,869,030.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock News HeadlinesNeurocrine Biosciences Appoints Dr. Keswani as CMOApril 4 at 8:51 AM | tipranks.comNeurocrine Biosciences names Sanjay Keswani as chief medical officerApril 4 at 8:30 AM | seekingalpha.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 4, 2025 | American Alternative (Ad)Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical OfficerApril 4 at 8:00 AM | prnewswire.comWells Fargo Sticks to Their Buy Rating for Neurocrine (NBIX)April 3 at 8:33 PM | markets.businessinsider.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $165.38 Average Price Target from BrokeragesApril 3 at 2:07 AM | americanbankingnews.comNeurocrine price target raised to $184 from $183 at JPMorganMarch 27, 2025 | markets.businessinsider.comNeurocrine Biosciences (NASDAQ:NBIX) Given New $184.00 Price Target at JPMorgan Chase & Co.March 27, 2025 | americanbankingnews.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $136.50 at the beginning of 2025. Since then, NBIX shares have decreased by 24.6% and is now trading at $102.88. View the best growth stocks for 2025 here. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Thursday, February, 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by $0.62. Neurocrine Biosciences had a trailing twelve-month return on equity of 13.38% and a net margin of 14.49%. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' Board of Directors approved a stock buyback plan on Friday, February 21st 2025, which authorizes the company to buy back $500,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 4.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued. Who are Neurocrine Biosciences' major shareholders? Top institutional investors of Neurocrine Biosciences include First Hawaiian Bank (0.01%), Central Pacific Bank Trust Division and Versant Capital Management Inc. Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Malcolm Lloyd-Smith, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, George J Morrow and Leslie V Norwalk. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings2/06/2025Today4/04/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$165.38 High Stock Price Target$219.00 Low Stock Price Target$114.00 Potential Upside/Downside+60.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$3.29 Trailing P/E Ratio31.27 Forward P/E Ratio24.04 P/E Growth0.77Net Income$341.30 million Net Margins14.49% Pretax Margin20.63% Return on Equity13.38% Return on Assets9.73% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.28 Sales & Book Value Annual Sales$2.36 billion Price / Sales4.36 Cash Flow$3.00 per share Price / Cash Flow34.35 Book Value$25.97 per share Price / Book3.96Miscellaneous Outstanding Shares99,704,000Free Float95,417,000Market Cap$10.26 billion OptionableOptionable Beta0.35 Social Links 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:NBIX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
